Durable complete remission with local therapies after neoadjuvant and adjuvant nivolumab in recurrent/metastatic head and neck cancer
Sign Up to like & getrecommendations! Published in 2022 at "Anti-Cancer Drugs"
DOI: 10.1097/cad.0000000000001422
Abstract: Up to 10–15% of patients with first-line recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) present with platinum-refractory disease. The anti-PD1 nivolumab is the first therapeutic option in this setting achieving a 19.2% objective… read more here.
Keywords: durable complete; head neck; metastatic head; disease ... See more keywords
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML.
Sign Up to like & getrecommendations! Published in 2023 at "Blood advances"
DOI: 10.1182/bloodadvances.2022009411
Abstract: Olutasidenib (FT-2102) is a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1). Overall, 153 IDH-1 inhibitor naïve patients with mIDH1R132 relapsed/refractory (R/R) acute myeloid leukemia (AML) received olutasidenib monotherapy 150 mg twice… read more here.
Keywords: induces durable; durable complete; relapsed refractory; 2102 induces ... See more keywords
Durable Complete Response in a Melanoma Patient With Unknown Primary, Associated With Sequential and Severe Multi-Organ Toxicity After a Single Dose of CTLA-4 Plus PD-1 Blockade: A Case Report
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2020.592609
Abstract: Monoclonal antibodies blocking PD-1 and CTLA-4 immunological checkpoints lead to durable tumor responses in a considerable number of advanced melanoma patients. Besides their anti-neoplastic efficacy, these immune checkpoint inhibitors cause a wide range of immune-related… read more here.
Keywords: report; melanoma patient; durable complete; complete response ... See more keywords
Durable complete response with a short course of streptozotocin plus doxorubicin combination in malignant metastatic insulinoma
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Cancer Research and Therapeutics"
DOI: 10.4103/0973-1482.188293
Abstract: Due to the cytotoxic effects of old chemotherapy regimens used in the islet cell tumors, capecitabine plus temozolomide combination has now become the first choice in the treatment of malignant insulinoma (MIoma). We present this… read more here.
Keywords: combination; short course; durable complete; course streptozotocin ... See more keywords